CareDx Q2 adjusted revenue grows 14%

CareDx

06/08/2025 21:12

Overview

CareDx Q2 adjusted rev grows 14% yr/yr

Co narrows full-year 2025 revenue guidance to $367 mln to $373 mln

Outlook

CareDx narrows full-year 2025 revenue guidance to $367 mln to $373 mln

Company expects full-year 2025 adjusted EBITDA of $29 mln to $33 mln

Result Drivers

ALLOSURE KIDNEY TESTING - Volumes grew nearly 20% yr/yr, driving testing services growth

CASH COLLECTIONS - Improved cash collections contributed to adjusted EBITDA gain

FINANCIAL DISCIPLINE - Financial discipline helped achieve adjusted EBITDA improvement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$86.70 mln
Q2 Adjusted EPS
Miss
$0.1
$0.12 (6 Analysts)
Q2 EPS
-$0.16
Q2 Adjusted Net Income
Miss
$5.60 mln
$6.56 mln (6 Analysts)
Q2 Net Income
-$8.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CareDx Inc is $26.00, about 50.6% above its August 5 closing price of $12.85

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nBw2n2vlra

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)